Literature DB >> 24725405

Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling.

Susann Weissmueller1, Eusebio Manchado2, Michael Saborowski2, John P Morris2, Elvin Wagenblast3, Carrie A Davis3, Sung-Hwan Moon4, Neil T Pfister4, Darjus F Tschaharganeh2, Thomas Kitzing2, Daniela Aust5, Elke K Markert6, Jianmin Wu7, Sean M Grimmond8, Christian Pilarsky5, Carol Prives4, Andrew V Biankin9, Scott W Lowe10.   

Abstract

Missense mutations in the p53 tumor suppressor inactivate its antiproliferative properties but can also promote metastasis through a gain-of-function activity. We show that sustained expression of mutant p53 is required to maintain the prometastatic phenotype of a murine model of pancreatic cancer, a highly metastatic disease that frequently displays p53 mutations. Transcriptional profiling and functional screening identified the platelet-derived growth factor receptor b (PDGFRb) as both necessary and sufficient to mediate these effects. Mutant p53 induced PDGFRb through a cell-autonomous mechanism involving inhibition of a p73/NF-Y complex that represses PDGFRb expression in p53-deficient, noninvasive cells. Blocking PDGFRb signaling by RNA interference or by small molecule inhibitors prevented pancreatic cancer cell invasion in vitro and metastasis formation in vivo. Finally, high PDGFRb expression correlates with poor disease-free survival in pancreatic, colon, and ovarian cancer patients, implicating PDGFRb as a prognostic marker and possible target for attenuating metastasis in p53 mutant tumors.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24725405      PMCID: PMC4001090          DOI: 10.1016/j.cell.2014.01.066

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  42 in total

1.  Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.

Authors:  Silvia Di Agostino; Sabrina Strano; Velia Emiliozzi; Valentina Zerbini; Marcella Mottolese; Ada Sacchi; Giovanni Blandino; Giulia Piaggio
Journal:  Cancer Cell       Date:  2006-09       Impact factor: 31.743

2.  A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint.

Authors:  Rachel Beckerman; Aaron J Donner; Melissa Mattia; Melissa J Peart; James L Manley; Joaquin M Espinosa; Carol Prives
Journal:  Genes Dev       Date:  2009-06-01       Impact factor: 11.361

Review 3.  Assessing TP53 status in human tumours to evaluate clinical outcome.

Authors:  T Soussi; C Béroud
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

4.  Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.

Authors:  S A Mehta; K W Christopherson; P Bhat-Nakshatri; R J Goulet; H E Broxmeyer; L Kopelovich; H Nakshatri
Journal:  Oncogene       Date:  2006-11-27       Impact factor: 9.867

5.  p73 independent of c-Myc represses transcription of platelet-derived growth factor beta-receptor through interaction with NF-Y.

Authors:  Anders Hackzell; Hidetaka Uramoto; Hiroto Izumi; Kimitoshi Kohno; Keiko Funa
Journal:  J Biol Chem       Date:  2002-08-06       Impact factor: 5.157

Review 6.  Mammalian iron transporters: families SLC11 and SLC40.

Authors:  Nicolas Montalbetti; Alexandre Simonin; Gergely Kovacs; Matthias A Hediger
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

7.  Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.

Authors:  P M Neilsen; J E Noll; S Mattiske; C P Bracken; P A Gregory; R B Schulz; S P Lim; R Kumar; R J Suetani; G J Goodall; D F Callen
Journal:  Oncogene       Date:  2012-07-16       Impact factor: 9.867

8.  MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer.

Authors:  Michela Garofalo; Young-Jun Jeon; Gerard J Nuovo; Justin Middleton; Paola Secchiero; Pooja Joshi; Hansjuerg Alder; Natalya Nazaryan; Gianpiero Di Leva; Giulia Romano; Melissa Crawford; Patrick Nana-Sinkam; Carlo M Croce
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

9.  Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205.

Authors:  T Hoehler; G von Wichert; C Schimanski; S Kanzler; M H Moehler; A Hinke; T Seufferlein; J Siebler; A Hochhaus; D Arnold; M Hallek; R Hofheinz; U T Hacker
Journal:  Br J Cancer       Date:  2013-08-20       Impact factor: 7.640

10.  Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis.

Authors:  P Dong; M Karaayvaz; N Jia; M Kaneuchi; J Hamada; H Watari; S Sudo; J Ju; N Sakuragi
Journal:  Oncogene       Date:  2012-07-30       Impact factor: 9.867

View more
  224 in total

1.  Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer.

Authors:  Luisa F Escobar-Hoyos; Alex Penson; Ram Kannan; Hana Cho; Chun-Hao Pan; Rohit K Singh; Lisa H Apken; G Aaron Hobbs; Renhe Luo; Nicolas Lecomte; Sruthi Babu; Fong Cheng Pan; Direna Alonso-Curbelo; John P Morris; Gokce Askan; Olivera Grbovic-Huezo; Paul Ogrodowski; Jonathan Bermeo; Joseph Saglimbeni; Cristian D Cruz; Yu-Jui Ho; Sharon A Lawrence; Jerry P Melchor; Grant A Goda; Karen Bai; Alessandro Pastore; Simon J Hogg; Srivatsan Raghavan; Peter Bailey; David K Chang; Andrew Biankin; Kenneth R Shroyer; Brian M Wolpin; Andrew J Aguirre; Andrea Ventura; Barry Taylor; Channing J Der; Daniel Dominguez; Daniel Kümmel; Andrea Oeckinghaus; Scott W Lowe; Robert K Bradley; Omar Abdel-Wahab; Steven D Leach
Journal:  Cancer Cell       Date:  2020-06-18       Impact factor: 31.743

2.  STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma.

Authors:  Yukihiro Otaka; Susumu Rokudai; Kyoichi Kaira; Michiru Fujieda; Ikuko Horikoshi; Reika Iwakawa-Kawabata; Shinji Yoshiyama; Takehiko Yokobori; Yoichi Ohtaki; Kimihiro Shimizu; Tetsunari Oyama; Jun'ichi Tamura; Carol Prives; Masahiko Nishiyama
Journal:  Clin Cancer Res       Date:  2017-01-13       Impact factor: 12.531

3.  p53 gain-of-function mutations promote metastasis via ENTPD5 upregulation and enhanced N-glycoprotein folding.

Authors:  Oleg Timofeev; Thorsten Stiewe
Journal:  Mol Cell Oncol       Date:  2017-02-03

4.  A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.

Authors:  Evangelia Loizou; Ana Banito; Geulah Livshits; Yu-Jui Ho; Richard P Koche; Francisco J Sánchez-Rivera; Allison Mayle; Chi-Chao Chen; Savvas Kinalis; Frederik O Bagger; Edward R Kastenhuber; Benjamin H Durham; Scott W Lowe
Journal:  Cancer Discov       Date:  2019-05-08       Impact factor: 39.397

5.  A new PDAC mouse model originated from iPSCs-converted pancreatic cancer stem cells (CSCcm).

Authors:  Anna Sanchez Calle; Neha Nair; Aung KoKo Oo; Marta Prieto-Vila; Megumi Koga; Apriliana Cahya Khayrani; Maram Hussein; Laura Hurley; Arun Vaidyanath; Akimasa Seno; Yoshiaki Iwasaki; Malu Calle; Tomonari Kasai; Masaharu Seno
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

Review 6.  Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape.

Authors:  Ammad Ahmad Farooqi; Zahid H Siddik
Journal:  Cell Biochem Funct       Date:  2015-07-07       Impact factor: 3.685

7.  Recombinant human adenovirus-p53 improves the outcome of mid-late stage pancreatic cancer via arterial infusion.

Authors:  Jinggang Mo; Meihua Lin; Bin He; Kai Tan; Chong Jin; Hao Jiang; Xuefeng Pan; Weidong Lin
Journal:  Oncol Lett       Date:  2017-09-25       Impact factor: 2.967

8.  Genomic analyses identify molecular subtypes of pancreatic cancer.

Authors:  Peter Bailey; David K Chang; Katia Nones; Amber L Johns; Ann-Marie Patch; Marie-Claude Gingras; David K Miller; Angelika N Christ; Tim J C Bruxner; Michael C Quinn; Craig Nourse; L Charles Murtaugh; Ivon Harliwong; Senel Idrisoglu; Suzanne Manning; Ehsan Nourbakhsh; Shivangi Wani; Lynn Fink; Oliver Holmes; Venessa Chin; Matthew J Anderson; Stephen Kazakoff; Conrad Leonard; Felicity Newell; Nick Waddell; Scott Wood; Qinying Xu; Peter J Wilson; Nicole Cloonan; Karin S Kassahn; Darrin Taylor; Kelly Quek; Alan Robertson; Lorena Pantano; Laura Mincarelli; Luis N Sanchez; Lisa Evers; Jianmin Wu; Mark Pinese; Mark J Cowley; Marc D Jones; Emily K Colvin; Adnan M Nagrial; Emily S Humphrey; Lorraine A Chantrill; Amanda Mawson; Jeremy Humphris; Angela Chou; Marina Pajic; Christopher J Scarlett; Andreia V Pinho; Marc Giry-Laterriere; Ilse Rooman; Jaswinder S Samra; James G Kench; Jessica A Lovell; Neil D Merrett; Christopher W Toon; Krishna Epari; Nam Q Nguyen; Andrew Barbour; Nikolajs Zeps; Kim Moran-Jones; Nigel B Jamieson; Janet S Graham; Fraser Duthie; Karin Oien; Jane Hair; Robert Grützmann; Anirban Maitra; Christine A Iacobuzio-Donahue; Christopher L Wolfgang; Richard A Morgan; Rita T Lawlor; Vincenzo Corbo; Claudio Bassi; Borislav Rusev; Paola Capelli; Roberto Salvia; Giampaolo Tortora; Debabrata Mukhopadhyay; Gloria M Petersen; Donna M Munzy; William E Fisher; Saadia A Karim; James R Eshleman; Ralph H Hruban; Christian Pilarsky; Jennifer P Morton; Owen J Sansom; Aldo Scarpa; Elizabeth A Musgrove; Ulla-Maja Hagbo Bailey; Oliver Hofmann; Robert L Sutherland; David A Wheeler; Anthony J Gill; Richard A Gibbs; John V Pearson; Nicola Waddell; Andrew V Biankin; Sean M Grimmond
Journal:  Nature       Date:  2016-02-24       Impact factor: 49.962

9.  EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis.

Authors:  Yu Zhao; Liya Ding; Dejie Wang; Zhenqing Ye; Yundong He; Linlin Ma; Runzhi Zhu; Yunqian Pan; Qiang Wu; Kun Pang; Xiaonan Hou; Saravut J Weroha; Conghui Han; Roger Coleman; Ilsa Coleman; R Jeffery Karnes; Jun Zhang; Peter S Nelson; Liguo Wang; Haojie Huang
Journal:  EMBO J       Date:  2019-02-05       Impact factor: 11.598

10.  The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas.

Authors:  Stephanie Downs-Canner; Mazen Zenati; Brian A Boone; Patrick R Varley; Jennifer Steve; Melissa E Hogg; Amer Zureikat; Herbert J Zeh; Kenneth K W Lee
Journal:  J Surg Oncol       Date:  2015-07-07       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.